Therefore, the pathway involving miR-27a-3p, Hoxa10, and Kv4.3 represents a newly discovered regulatory mechanism crucial to myocardial cell hypertrophy triggered by Ang II, providing a novel target for the clinical strategies aimed at preventing and treating cardiac hypertrophy and HF. This evidence concerns the gene AGT and cardiac hypertrophy.